|
Inclusion criteria
|
Inclusion criteria of liver cancer
1) The age is from 18 to 75 years old, gender is not limited;
2) Late stage HCC (non operative or metastatic) confirmed by histology / cytology and lack of criteria patients who are treated or do not have standard treatment conditions;
3) Child Pugh liver function rating: A, B;
4) There is at least one measurable focus (according to the recist1.1 standard);
5) At least 4 weeks or more than 5 half-lives after the last anti-tumor treatment; surgical treatment more than 3 months; the end time of the last interventional therapy was more than 1 month;
6) Expected survival time >= 3 months;
7) The MELD score was less than 9;
8) Can cooperate to observe adverse events and curative effect;
9) No other anti-tumor concomitant treatment (including steroid drugs);
10) ECoG score <= 2;
11) Serum albumin >= 30g / L, ALT <= 190u / L, AST <= 200u / L, serum TBIL <= 1.5 x ULN, electrolyte normal or normal after treatment, proteinuria = 0 ~ 1 +, blood creatinine <= 1.5 × ULN;
12) The blood routine examination standard should be: HB >= 80g / L; ANC >= 1.5 x 10^9 / L; PLT >= 70 x 10^9/L;
13) Patients voluntarily sign written informed consent.
Inclusion criteria of lung cancer
1) Voluntarily participate in the clinical trial, understand the research procedure and have signed the informed consent;
2) Age: male or female patients aged 18-75 years;
3) Patients with locally advanced or metastatic small cell or non-small cell lung cancer confirmed by histology or cytology;
4) According to the standard of ECoG, the physical condition was 0-2 points;
5) The expected life span is not less than 3 months;
6) According to recist1.1 evaluation standard of solid tumor efficacy, patients have at least one imaging (CT, MRI) can measure the focus, the longest diameter is required to be >= 10 mm (in case of lymph nodes, the short axis is required to be >= 15 mm) (brain metastasis is not the only measurable lesion);
7) The subjects must have proper organ function and meet the following laboratory test results before entering the group: Bone marrow reserve is basically normal: neutrophil absolute count >= 1.5 x 10^9 / L, platelet >= 100 x 10^9 / L, and hemoglobin >= 80g / L; Liver function is basically normal: albumin in serum >= 3.0 g / dl; bilirubin <= 1.5 x ULN, ALT and Ast <= 2.5 x ULN, ALT or AST <= 5 x ULN in case of liver metastasis; Normal renal function: creatinine <= 1.5 x ULN or creatinine clearance rate >= 60 ml / min in 24 hours; Coagulation function is basically normal: INR <= 1.5 x ULN, APTT <= 1.5 x ULN; Cardiac function: left ventricular ejection fraction >= 50%; ECG is basically normal, QT interval in men <= 450 ms, female <= 470 MS;
8) The patient must recover from the previous treatment toxicity to <= level 1, except for alopecia and previous platinum containing treatment of level 2 related neuropathy (CTC AE 5.0);
|
|
Exclusion criteria：
|
Exclusion criteria for liver cancer
1) Severe cirrhosis, liver atrophy, portal hypertension, ascites of medium or more quantity;
2) Previous history of liver transplantation;
3) Diffuse liver cancer, tumor thrombus or liver obstructive jaundice in the main portal vein, and liver failure, it is difficult to control hepatic encephalopathy;
4) Double cancer and multiple cancer patients;
5) Active upper gastrointestinal ulcer, obvious vomiting, chronic diarrhea, intestinal obstruction, absorption disorder , etc.. Other patients known to affect drug absorption, distribution, metabolism or clearance;
6) The toxicity of previous anticancer therapy has not been restored to level I or completely recovered from previous surgery;
7) Active bleeding or abnormal coagulation (PT > 16S, APTT > 43S, TT > 21s, INR >= 2), with bleeding tendency or undergoing thrombolysis or anticoagulation treatment;
8) Taking drugs that may prolong QTc and / or TDP or affect drug metabolism (such as sedation agent) at the same time;
9) Suspected allergy to Astragalus / Panax notoginseng, oncolytic virus or similar drugs and their metabolites or their pharmaceutical accessories;
10) Pregnant or lactating women, or those who are unwilling to use contraception during the trial;
11) Any significant clinical and laboratory abnormalities that the investigator considers to affect the safety assessment;
12) Brain metastasis, meningeal metastasis or various mental disorders;
13) Glomerular filtration rate was significantly abnormal (creatinine clearance rate < 60ml / min, serum creatinine
>= 1.5 x ULN);
14) They are receiving broad-spectrum antiviral drugs, such as amantadine, acyclovir, ganciclovir and lidocaine bavelin, et al. 3 days of discontinuation of Antihepatitis B treatment;
15) Autoimmune diseases;
16) HIV, HCV, HDV infection;
17) Those who participated in clinical trials of any drugs or medical devices within 3 months before the trial.
Exclusion criteria for lung cancer
1) Those who have a history of allergy to Astragalus / notoginseng and their metabolites or their pharmaceutical excipients (with or without activity);
2) Have taken other drugs in clinical trials within 30 days before the first administration;
3) In addition to lung cancer, in the past five years, there has been a diagnosis of another kind of malignant tumor (excluding those already treated malignant tumors, such as completely resected basal cell carcinoma and carcinoma in situ;
4) Major surgical treatment, open biopsy or significant trauma within 2 weeks prior to first use of study drug. In all cases, the patient must be fully recovered and stable before treatment;
5) Subjects with active gastrointestinal disease or other diseases may significantly affect drug absorption, metabolic or excretory factors;
6) Uncontrollable chronic systemic complications (such as severe chronic lung, liver, kidney, heart or visceral diseases);
7) According to NYHA standard, patients with grade III-IV cardiac insufficiency;
8) QTc of baseline ECG was prolonged (QTCF: male > 450 ms, female > 470 MS);
9) Any uncontrollable serious clinical research related problems (such as uncontrolled psychosis state, uncontrolled pleural effusion and / or pericardial effusion, uncontrolled complications, including mobility infection, arterial thrombosis and symptomatic pulmonary embolism;
10) Presence of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment previous medical history, or evidence of any qualitative lung disease during clinical activity;
11) The subjects were in the stage of acute infection and needed drug treatment and antiviral treatment;
12) HIV, HBV and HCV were positive in the subjects (number of copies of HBV >= 104 copies / ml, copy number of HCV >= 10^3 copies / ml);
13) According to the judgment of the researcher, the objective conditions (including patients' psychological state, family relationship, social factors or place domain factors, etc.) make the patients unable to complete the planned study or the subjects have other factors that may cause the study to be factors of forced termination;
14) Pregnant or lactating women;
15) Autoimmune diseases.
|
